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The utility of novel oral soluble guanylate cyclase (sGC) stimulators (vericiguat 
and riociguat), in patients with reduced or preserved ejection fraction heart failure 
(HFrEF/HFpEF) is currently unclear.
AIM 
To determine the efficacy and safety of sGC stimulators in HF patients.
METHODS 
Multiple databases were searched to identify relevant randomized controlled 
trials (RCTs). Data on the safety and efficacy of sGC stimulators were compared 
using relative risk ratio (RR) on a random effect model.
RESULTS 
Six RCTs, comprising 5604 patients (2801 in sGC stimulator group and 2803 
placebo group) were included. The primary endpoint (a composite of 
cardiovascular mortality and first HF-related hospitalization) was significantly 
reduced in patients receiving sGC stimulators compared to placebo [RR 0.92, 95% 
confidence interval (CI): 0.85-0.99, P = 0.02]. The incidence of total HF-related 
hospitalizations were also lower in sGC group (RR 0.91, 95%CI: 0.86-0.96, P = 
0.0009), however, sGC stimulators had no impact on all-cause mortality (RR 0.96, 
95%CI: 0.86-1.07, P = 0.45) or cardiovascular mortality (RR 0.94, 95%CI: 0.83-1.06, 
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P= 0.29). The overall safety endpoint (a composite of hypotension and syncope) 
was also similar between the two groups (RR 1.50, 95%CI: 0.93-2.42, P = 0.10). By 
contrast, a stratified subgroup analysis adjusted by type of sGC stimulator and HF 
(vericiguat vs riociguat and HFrEF vs HFpEF) showed near identical rates for all 
safety and efficacy endpoints between the two groups at a mean follow-up of 19 
wk. For the primary composite endpoint, the number needed to treat was 35, the 
number needed to harm was 44.
CONCLUSION 
The use of vericiguat and riociguat in conjunction with standard HF therapy, 
shows no benefit in terms of decreasing HF-related hospitalizations or mortality.
Key Words: Vericiguat; Riociguat; Soluble guanylate cyclase; Heart failure; Guanylate 
cyclase stimulator
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Recently soluble guanylate cyclase (sGC) stimulators (vericiguat and 
riociguat) have emerged as a novel treatment for heart failure with reduced or 
preserved ejection fraction. Data published in literature revealed no additional benefits 
to guideline-based medical therapy in reducing incidence of heart failure 
hospitalization and mortality with sGC stimulator use. Large scale studies are required 
to determine the efficacy of sGC stimulators in patients with heart failure.
Citation: Ullah W, Mukhtar M, Al-Mukhtar A, Saeed R, Boigon M, Haas D, Rame E. Safety 
and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic 




There are an estimated 6.5 million adults in the United States suffering from heart 
failure (HF) with the disease accounting for nearly 1 in every 8 deaths[1] Approximately 
1 million[2,3] HF-related hospitalizations (HHF) occur annually, accounting[4] for over 
6.5 million hospital days and $37.2 billion in costs every year[1]. This economic burden 
has risen dramatically over the past two decades, with the increasing prevalence of 
risk factors for HF adding to new cases and better therapies adding to increased life 
expectancy among HF patients[1].
Despite traditional pharmacologic management with beta-blockers, angiotensin-
converting-enzyme inhibitors (ACEI) and mineralocorticoid receptor antagonists to 
reduce HF exacerbations and mitigate clinical progression, overall prognosis remains 
dismal[2]. This has led researchers to target alternative pathways involved in the 
pathogenesis of HF, with promising research focusing on soluble guanylate cyclase 
(sGC) and the natriuretic peptide system (NPS)[3,4].
Both pathways influence myocardial perfusion and ventricular function through 
their common second messenger: Cyclic guanosine monophosphate (cGMP). The 
therapeutic augmentation of NPS with a combination angiotensin receptor–neprilysin 
inhibitor (sacubitril) has proven to be immensely beneficial, to the extent that the 
pioneering PARADIGM trial was halted early given the clear benefits in terms 
reducing mortality [risk ratio (RR) 0.84, 95% confidence interval (CI): 0.76-0.93, P < 
0.001] and hospitalization (by 21%, P < 0.001) compared to ACEI alone[5]. However, the 
use of conventional vasodilators (nitrites and nitrates) to achieve soluble GC activation 
has met with more mixed results, with the development of tolerance, hypotension and 
failure of treatment being reported[6]. These discouraging findings have been attributed 
to a relative deficiency of sGC due to reduced nitric oxide (NO) bioavailability and 
endothelial dysfunction in HF leading to impaired cyclic GMP generation[7].
Novel sGC stimulators (vericiguat and riociguat) have shown advances over 
traditional vasodilators[6], by augmenting the cGMP signaling pathway, independent 
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of NO and enhancing the effect of endogenous NO[2,8]. In contrast to the conventional 
therapeutic approach of antagonizing counterregulatory neurohormonal pathways, 
such as by phosphodiesterase inhibitors, or by addition of exogenous NO, sGC 
stimulators sensitize soluble GC to endogenous NO, thereby potentially having more 
efficacy for HF treatment[9].
In this regard, multiple clinical trials have attempted to explore the utility of 
vericiguat and riociguat in patients with HF[2,8]. The VICTORIA (vericiguat Global 
Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial recently 
established that vericiguat in patients with HFrEF can reduce the risk of 
cardiovascular mortality and HF-related hospitalizations[2]. These findings, however, 
stand in contrast to previous trials that have not shown any consistent benefit with 
sGC stimulators. The ambiguity of current literature and the absence of any definite 
large-scale studies to determine the true merits of sGC stimulators in patients with HF, 
motivated us to perform this meta-analysis.
MATERIALS AND METHODS
Search strategy and data extraction
The MEDLINE (PubMed, Ovid), Embase, Clinicaltrials.org and Cochrane databases 
were queried with various combinations of medical subject headings (MeSH) to 
identify relevant articles. There were no language or time restrictions placed. 
Backward snowballing was performed to retrieve unidentified studies that were 
missed on the initial search. The MeSH used included two subsets: One for HF using 
the terms like “heart failure,” “HFrEF,” “HFpEF,” “CHF,” “cardiac failure,” and the 
other for sGC using “guanylate cyclase stimulators,” “sGC,” “vericiguat,” and 
“riociguat.” The two subsets of MeSH were combined in a 1:1 combination using 
Boolean operators. Results from all possible combinations were downloaded into an 
EndNote library. All randomized control trials (RCT) until March 31, 2020, comparing 
the safety and efficacy of sGC in HF were evaluated for inclusion.
Patients with HFrEF and HFpEF [New York Heart Association (NYHA) class II-IV], 
on optimal guideline-based medical therapy requiring hospitalization or outpatient 
intravenous (IV) diuretics, were included in this study. Patients requiring IV inotropic 
support, in acute decompensated HF or requiring mechanical device support were 
excluded, so were patients using suboptimal doses of vericiguat (< 10 mg daily) or 
riociguat (< 2 mg daily), nitrates, alternative sGC stimulators or PDE inhibitors.
The primary efficacy endpoint was a composite of the first hospitalization for HF 
and death from cardiovascular causes. The secondary efficacy endpoints were the 
components of the primary outcome, total HF-related hospitalizations, cardiovascular 
and all-cause mortality. Safety endpoints included anemia, hypotension, syncope, and 
a composite of the later two. A detailed search map and definition of outcomes are 
given in the Supplementary Appendix.
Data and quality analysis
The statistical analysis was performed using the Cochran–Mantel–Haenszel test on a 
random-effect model to calculate RR for the dichotomous outcomes of RCTs. The 
probability value of P < 0.05 was considered statistically significant. The “test for 
overall effect” was reported as the z value corroborating the inference from the 95%CI. 
Subgroup analysis based on the choice of sGC stimulator and type of HF was also 
performed. Higgins I-squared (I2) statistical model was used to assess variations in 
outcomes of the included studies. I2 less than 40% corresponded to low heterogeneity. 
Depending upon the strength of evidence for heterogeneity (P value from the chi-
square χ2 analysis), I2 of 41 to 74% indicated moderate (P ≥ 0.05) or moderate to severe (
P ≤ 0.05) and I2 of 75% or higher suggested substantial heterogeneity. Publication bias 
was illustrated graphically using a funnel plot. The methodological quality assessment 
of the included RCTs was performed using the Cochrane collaboration tool for the 
systematic review and meta-analysis, where each study was screened for five different 
types of bias (selection, performance, detection, attrition, and reporting bias). All 
statistical analysis was performed using the Cochrane Review Manager (RevMan) 
version 5.3.
Quality of the included studies
The overall quality of the included RCTs was high (Figure 1). Due to adequate 
randomization and allocation concealment, the risk of selection bias was low. The risk 
of performance and detection bias were reduced with appropriate blinding of 
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Figure 1  Summary and detailed methodological quality of the included studies. A: Summary of the included studies; B: Detailed methodological 
quality of the included studies.
participants and outcomes, respectively. Similarly, reporting bias across all studies 
was decreased due to an adequate description of the study results. The fact that most 
RCTs used an “intention to treat model” or had a minimal loss at follow-up, the risk of 
attrition bias was low.
RESULTS
Search results and study characteristics
The initial search revealed 1905 articles. After the removal of irrelevant and duplicate 
items, 43 studies were selected for full-text review. Of these, 37 articles were excluded 
based on our selection criteria, 6 articles (all RCTs) qualified for quantitative 
analysis[2,8,10-13]. The Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram is shown in Figure 2.
A total of 5604 patients, 2801 in the sGC stimulator group, and 2803 in the placebo 
group were included. The mean age of patients receiving sGC stimulator was 64 and 
for the placebo group 62 years; comprising 59% and 57% male patients, respectively. 
Three of the included trials used vericiguat (1.25, 2.5, 5, or 10 mg), and three RCTs 
used riociguat (0.5, 1, or 2 mg) in the experimental arm. Baseline characteristics of 
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Figure 2  Flow diagram of the included studies showing reasons for exclusion.
treatment and placebo groups were comparable. Use of the concomitant guideline-
directed HF medical therapy was also balanced between the two groups. The 
VICTORIA and the (soluble guanylate cyclase stimulator in heart failure patients with 
preserved and reduced EF) SOCRATES trials used vericiguat in HFrEF patients. These 
patients had a mean EF of 29% and NYHA class III-IV. The median baseline N-
terminal pro-B-type natriuretic peptide (NT-proBNP) levels were 2816 pg/mL and 
3076 pg/mL, respectively. The SOCRATES-PRESERVED trial used the Kansas City 
cardiomyopathy questionnaire-clinical summary score to gauge symptomatic 
improvement in the HFpEF population. The DILATE-1 (acute hemodynamic effects of 
riociguat in patients with pulmonary hypertension associated with diastolic heart 
failure) investigated riociguat in the HFpEF population. The PAH-CHD (pulmonary 
arterial hypertension after correction of congenital heart disease) trial included 
younger patients with a mean 38 ± 15 years. The PAH-CHD and the LEPHT (left 
ventricular systolic dysfunction associated with pulmonary hypertension) had 100% 
and 97% of HF patients with NYHA II-III, respectively. The overall follow-up duration 
ranged from 12-43 wk, with a mean follow up of 19 wk. The detailed baseline 
characteristics, inclusion criteria, and definitions of outcomes are given in 
Supplementary Tables 1-3, respectively.
Pooled analysis of overall studies
Pooled efficacy endpoints: Four studies comprising 5530 patients (2752 sGC 
stimulator and 2778 placebo) compared the primary composite endpoint 
(cardiovascular mortality plus first-time hospitalization) between the sGC stimulators 
and the control group. At a mean follow-up of 21-wk, a significantly lower rate of the 
primary endpoint was obtained with the use of sGC stimulator in HF patients (RR 
0.92, 95%CI: 0.85-0.99, P = 0.02) (Figure 3A). Similarly, compared to placebo, the rate of 
total HF-related hospitalizations was significantly lower (RR 0.91, 95%CI: 0.86-0.96, P = 
0.000.9) in patients on sGC stimulators. However, the incidence of cardiovascular and 
all-cause mortality remained identical in both groups at a mean follow up of 19-mo 
(RR 0.94, 95%CI: 0.83-1.06, P = 0.29 and RR 0.96, 95%CI: 0.86-1.07, P = 0.45, 
respectively) (Figure 3B). Six studies consisting of 5604 patients (2801 sGC stimulator 
and 2803 placebo) contributed to the later comparison (Figure 4). There was no 
heterogeneity among the outcomes of the included studies (I2 = 0%).
Pooled safety endpoints: Six studies comprising 5596 patients (2793 sGC stimulator 
and 2803 placebo) were used to calculate the incidence of net adverse events of clinical 
interest (NAECI) (a composite of hypotension and syncope). The rate of NAECI was 
1.5 times higher but statistically non-significant in patients receiving sGC stimulators 
compared to placebo (RR 1.50, 95%CI: 0.93-2.41, P = 0.10) (Figure 3B). The incidence of 
hypotension (RR 1.47, 95%CI: 0.93-2.33, P = 0.10) and syncope (RR 1.18, 95 CI: 0.90-
1.55, P = 0.24) were also numerically higher with the use of sGC stimulator use by 47% 
and 18% respectively; however, none of these differences reach the level of statistical 
significance. The incidence of anemia was significantly higher in sGC group (RR 1.33, 
95%CI: 1.08-1.64, P = 0.007). There was minimal heterogeneity among the studies 
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Figure 3  Forest plot for the primary composite endpoint overall side-effects showing an individual and pooled risk ratio for randomized 
controlled trials comparing soluble guanylate cyclase stimulators to control. A: Pooled composite endpoint; B: Overall side-effects. The pooled risk 
ratio (RR) with 95% confidence interval (CI) were calculated using random-effects models. Weight refers to the contribution of each study to the overall pooled 
estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial’s RR, respectively. The diamonds signify the pooled 
RR; the diamond’s centre denotes the point estimate and width denotes the 95%CI. CI: Confidence interval; sGC: Soluble guanylate cyclase.
comparing NAECI and hypotension (I2 = 35% and I2 = 20%, respectively) .
Net clinical benefit: The overall number needed to treat (NNT) for the primary 
composite endpoint by adding vericiguat to the standard guideline-directed HF 
therapy was 35 (95%CI: 18.7-332.2). The overall number needed to harm (NNH) for 
NAECI was 44 (95%CI: 25.2-180). The net clinical benefit (NCB) was 9, indicating 
futility. The overall NNT to prevent one death due to any-cause was 142 (95%CI: 36.3-
74.2) and to prevent one death from cardiovascular cause was 111 (95%CI: 35.3-96.7). 
None of the NNT values was statistically significant, as evidenced by the cross-over of 
its CI with the NNH.
Subgroup sensitivity analysis
A stratified analysis of prespecified subgroups adjusted on the type of HF (HFrEF and 
HFpEF) and choice of experimental regimen (vericiguat and riociguat) showed 
significant deviation from the pooled results. Two studies comprising 5233 patients 
(2616 sGC stimulator and 2617 placebo) contributed to the comparison of vericiguat 
and placebo agents in HFrEF patients. In contrast to the pooled results, there was no 
significant difference in the incidence of primary composite endpoint between patients 
receiving vericiguat and placebo for HFrEF (RR 0.84, 95%CI: 0.58-1.21, P = 0.24). 
Similarly, the rate of primary composite endpoint remained identical across patients 
on placebo and those receiving riociguat for HFrEF (RR 0.97, 95%CI: 0.54-1.76, P = 
0.92) or HFpEF (RR 0.78, 95%CI: 0.24-2.56, P = 0.68) (Supplementary Figure 1). 
Compared to placebo, there was no significant difference in the rate of total HF-related 
hospitalizations across HFrEF patients receiving vericiguat (RR 0.84, 95%CI: 0.60-1.20, 
P = 0.34) or riociguat (RR 0.97, 95%CI: 0.54-1.76, P = 0.92) and HFpEF patients on 
riociguat (RR 0.68, 95%CI: 0.18-2.64, P = 0.58) (Supplementary Figure 2).
The incidence of all-cause mortality stratified by the type of sGC stimulators or type 
of HF mirrored the overall results. A similar rate of mortality was obtained between 
patients on placebo vs those on vericiguat (RR 0.96, 95%CI: 0.86-1.07, P = 0.43) or 
riociguat (RR 1.97, 95%CI: 0.32-12.16, P = 0.46) (Supplementary Figure 3). Both HFrEF 
(5369 patients, 2648 sGC stimulator and 2685 placebo) and HFpEF (200 patients, 94 
sGC stimulator and 106 placebo group) followed the pooled results of all-cause 
mortality, showing a similar incidence of mortality between the two groups (RR 0.96, 
95%CI: 0.86-1.07, P = 0.44 and RR 1.45, 95%CI: 018-11.54, P = 0.73, respectively) (
Supplementary Figure 4). Sensitivity analysis by the exclusion of PAH-CHD study also 
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Figure 4  Forest plot for hospitalizations, cardiovascular and all-cause mortality showing an individual and pooled risk ratio for 
randomized controlled trials comparing soluble guanylate cyclase stimulators to control. A: Hospitalizations; B: Cardiovascular; C: All-cause 
mortality. CI: Confidence interval; sGC: Soluble guanylate cyclase.
did not alter the results of pooled analysis (RR 0.96, 95%CI: 0.86-1.07, P = 0.45) (
Supplementary Figure 5).
Publication bias
The funnel plot showed asymmetry, indicating the possibility of publication bias. 
(Figure 5) The vertical axis of the plot used standard error to estimate the sample size 
of the study, plotting large population studies on top and smaller at the bottom. The 
horizontal spread reflected the power and effect size of the included studies. One can 
argue that it is difficult to differentiate between “findings by chance” and “real 
asymmetry,” as only six articles were assessed for potential publication bias. As 
pointed by Sterne et al[14]. in a study of fewer than ten articles, it is difficult to ascertain 
publication bias.
DISCUSSION
To our knowledge, this is the largest study performed to assess the safety and efficacy 
of novel sGC stimulators (vericiguat and riociguat) in patients with HF. The results 
were drawn from 6 RCTs, comprising 5604 patients. In the combined analysis, among 
patients with high-risk HF (NYHA class II-IV), the addition of sGC stimulators to 
current guideline-based medical therapy showed a modest decrease in risk of the 
primary composite endpoint (first HF hospitalization plus cardiovascular death) by 
8%. With a similar decrease in HF-related total hospitalization by 9%. However, these 
benefits were attenuated when the pooled results were matched based on the type of 
HF and choice of sGC stimulator. Neither vericiguat nor riociguat groups reached the 
threshold of statistical significance when the efficacy endpoints (hospitalization and 
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Figure 5  Funnel plot showing possible publication bias. RR: Risk ratio.
death) were stratified by HFrEF and HFpEF. Similarly, compared to the control group, 
both vericiguat and riociguat failed to lower the incidence of cardiovascular or all-
cause mortality, irrespective of the type of HF or duration of follow-up. Moreover, the 
incidence of NAECI and its components (hypotension and syncope) in the intervention 
group were 1.5 times higher than the placebo group. Briefly, our analysis did not show 
the same positive findings seen in the recent VICTORIA trial and highlight the 
ambiguity in the use of sGC stimulators, until more definitive evidence is available (
Supplementary Figure 6).
It is interesting to compare our combined results with all included RCTs. The 
SOCRATES-PRESERVED and the SOCRATES-REDUCED trials used vericiguat in 
patients with HFpEF and HFrEF, respectively[10,11]. These trials were primarily 
designed to determine the optimal dose and tolerability of vericiguat. While on pooled 
analysis, the relative difference in the NT-proBNP levels was identical, the 
SOCRATES-REDUCED did show a significant dose-response relationship. Compared 
to placebo, a higher vericiguat dose of 10 mg was associated with greater reductions in 
NT-proBNP (P = 0.02) and significant improvement in LVEF (+1.5% vs +3.7%, P = 0.02) 
at 3 mo follow-up[11]. Similarly, the SOCRATES-PRESERVED trial showed a substantial 
improvement in the functional and symptomatic status of the HFpEF patients 
(increase in KCCQ-CSS by more than 5 points) on the 10 mg dose of vericiguat at 3 
mo[10]. Both SOCRATES-PRESERVED and REDUCED trials used surrogate markers of 
disease severity and were relatively underpowered to gauge hard clinical outcomes 
(mortality and hospitalizations).
Three of the included RCTs compared the merits of riociguat against a placebo in 
both HFrEF and HFpEF patients. The PATENT-1 (the pulmonary arterial hypertension 
sGC-stimulator trial-1) and its long-term extension study PATENT-2 were unique in 
terms of inclusion criteria and assessment of outcomes. Riociguat was found to be 
associated with a decrease in the mean NT-proBNP levels, improved 6-minute walking 
distance (6MWD) and pulmonary vascular resistance (PVR) in patients with PAH-
CHD[12]. Both LEPHT and DILATE-1 trials demonstrated a significant increase in the 
stroke volume (P = 0.001 and P = 0.04) in their respective HFrEF and HFpEF patient 
populations. However, there was no significant decrease in the mean pulmonary 
arterial pressure (PAP), the primary endpoint, even at the maximally tolerated dose of 
riociguat (2 mg)[8,13]. These trials were also underpowered to assess major clinical 
endpoints and had variability in dose-response outcomes, limiting their utility.
The more contemporary VICTORIA trial was adequately powered and specifically 
designed to measure clinically relevant outcomes[2]. The trial used a cox-regression-
model to calculate a sample size of 5050 patients, who were hospitalized with the 
diagnosis of HFrEF. Both vericiguat and placebo groups in the trial were appropriately 
matched, minimizing ascertainment bias, but had a high rate of noncompliance and 
loss to follow-up. At a median follow-up of 10 mo, 24% of the vericiguat and 22% of 
the placebo arm had discontinued the trial regimen. While this amount of 
nonadherence was anticipated and an “intention to treat model” was used to reduce 
its impact on the overall results, the pooled difference in the primary composite 
endpoint was modest (RR 0.90, 95%CI: 0.82-0.98, P = 0.02). The incidence of 
cardiovascular mortality was near identical in the vericiguat and placebo groups 
(12.9% vs 13.9%, P = 0.83), indicating that the primary outcome was driven by the 
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lower rate of HF-related hospitalization in the vericiguat group (38.3% vs 42.4%, P = 
0.02)[2]. By contrast, our pooled analysis of vericiguat in HFrEF population showed no 
inter-group difference in both the incidence of the primary composite (P = 0.34), 
cardiovascular mortality (P = 0.29), and total HF-related hospitalizations (P = 0.34). 
Nonetheless, mirroring our pooled results, the VICTORIA trial showed no significant 
difference in the incidence of all-cause mortality between vericiguat and the placebo 
groups (20.3% vs 21.2%, P = 0.38). This underscores that the lower hospitalization rate 
in the vericiguat arm did not translate into clinical survival benefits. Together, these 
findings call for caution while interpreting the findings of the VICTORIA trial.
The present meta-analysis sought to address the overall discrepancies by 
systematically adjusting the definition of primary composite outcome and by 
excluding patients on the suboptimal dose of sGC stimulators. By design, our study 
prevents the influence of both known and unknown confounding factors due to the 
inclusion of high-quality studies. Our study showed no clinical benefits of sGC 
stimulator in terms of reducing mortality or HF-related hospitalization when the 
overall outcomes were stratified by type of HF and regimen of trial medication. These 
findings contrast with the most contemporary VICTORIA trial, which showed a 
decrease in the incidence of HF-related total hospitalizations and death from 
cardiovascular causes. Also unique was a demonstration of the consistent 
ineffectiveness of vericiguat and riociguat to reduce all-cause mortality across all 
included trials. Moreover, the calculation of the net clinical benefit may serve to inform 
clinical decision making, suggesting that sGC stimulators offer no benefits and could 
potentially be harmful.
Limitations
Our study is constrained by the limitations of the included studies. Patient-level data 
were missing to measure the impact of non-compliance on overall clinical outcomes. 
Long term follow-up data was lacking in more than half of the included studies, 
limiting our ability to calculate their predictive effects. Some studies focused on non-
clinical primary outcomes (pro-BNP, PAP) neglecting a significant amount of clinical 
complications such as myocardial infarction and mortality, reducing the precision of 
estimated complications. Due to the paucity of long-term follow-up data, it is unclear 
if these results could be extrapolated to patients with HFpEF. The ongoing DYNAMIC 
study might shed more light on the efficacy of sGC in patients with HFpEF[15].
It can also be argued that the assessment of the efficacy and safety of the sGC 
stimulators is a bivariate exercise, and summarizing it in a unidimensional variable 
(net clinical benefit) could be misleading. For example, a large number of relatively 
minor episodes of hypotension versus a small improvement in HF-related 
hospitalization rate may lead to a negative calculated Net Clinical Benefit (NCB). Still, 
given the vast disparity between the impact on the quality of life between an episode 
of hypotension versus HF-related hospitalization, it may falsely undervalue the benefit 
of therapy. Therefore, the NCB value should preferably be interpreted in the context of 
the nature of both adverse and beneficial events, without committing to value 
judgment. That being said, in our case, we found no significant beneficial effect of sGC 
stimulators and a higher incidence of adverse effects rendering this a moot point.
CONCLUSION
Vericiguat and riociguat offer no additional benefits to current guideline-based 
medical therapy in terms of reducing the incidence of hospitalization or mortality in 




Despite treatment with traditional pharmacologic management, patients with heart 
failure (HF) have a dismal prognosis, with approximately 1 million HF-related 
hospitalizations (HHF) occurring annually, accounting for over 6.5 million hospital 
days and $37.2 billion each year.
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Research motivation
This has led researchers to study the efficacy of alternate drugs in preventing HF 
exacerbations, which include soluble guanylate cyclase (sGC) stimulators vericiguat 
and riociguat. Multiple clinical trials have attempted to explore the utility of vericiguat 
and riociguat in patients with HF. However, there a lack of large scale studies to 
determine the true merits of sGC stimulators in patients with HF.
Research objectives
Therefore, we performed this meta-analysis to determine the efficacy and safety of 
sGC stimulators in HF patients.
Research methods
The MEDLINE (PubMed, Ovid), Embase, Clinicaltrials.org and Cochrane databases 
were queried with various combinations of medical subject headings (MeSH) to 
identify relevant articles. All randomized control trials (RCT) until March 31, 2020, 
comparing the safety and efficacy of sGC in HF were evaluated for inclusion. The 
primary efficacy endpoint was a composite of the first hospitalization for HF and 
death from cardiovascular causes. The secondary efficacy endpoints were the 
components of the primary outcome, total HF-related hospitalizations, cardiovascular 
and all-cause mortality. The statistical analysis was performed using the 
Cochran–Mantel–Haenszel test on a random-effect model to calculate relative risk (RR) 
for the dichotomous outcomes of RCTs. The overall quality of the included RCTs was 
high.
Research results
Six RCTs comprising 5604 patients (2801 sGC stimulator and 2803 placebo) were 
included. The primary endpoint (a composite of cardiovascular mortality and first HF-
related hospitalization) was reduced in patients receiving sGC stimulators compared 
to placebo [RR 0.92, 95% confidence interval (CI): 0.85-0.99, P = 0.02]. The incidence of 
total HF-related hospitalizations were also lower in sGC group (RR 0.91, 95%CI: 0.86-
0.96, P = 0.0009), however, sGC stimulators had no impact on all-cause and 
cardiovascular mortality (RR 0.96, 95%CI: 0.86-1.07, P = 0.45) and (RR 0.94, 95%CI: 
0.83-1.06, P = 0.29), respectively. The overall safety endpoints (composite of 
hypotension and syncope) were also identical between the two groups (RR 1.50, 
95%CI: 0.93-2.42, P = 0.10). For the primary composite endpoint, the number needed to 
treat was 35, the number needed to harm was -44 and the overall net clinical benefit 
was -9.
Research conclusions
Data published in literature revealed no additional benefits to guideline-based medical 
therapy in reducing incidence of HF hospitalization and mortality with sGC stimulator 
use. Large scale studies are required to determine the efficacy of sGC stimulators in 
patients with HF.
Research perspectives
As it is unclear whether sGC stimulators have any additional benefit in improving the 
prognosis of HF patients due to a lack of substantial research, large scale studies are 
needed to determine their efficacy in reducing HF related hospitalization rates.
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